Core Viewpoint - Eco Oro Minerals Corp. has completed the second tranche of a private placement of 2025 contingent value rights certificates, raising a total of US$4.5 million to support its arbitration proceedings against the Republic of Colombia [1][5]. Group 1: Private Placement Details - The private placement was completed in two tranches: the first tranche raised US$4,000,000 on August 7, 2025, and the second tranche raised US$500,000 on March 16, 2026 [1]. - The proceeds from the private placement will primarily be used to support the company's application to annul a damages award from an arbitration tribunal that awarded no monetary compensation to the company [1]. Group 2: Contingent Value Rights (CVRs) - The company has issued a new class of contingent value rights certificates (Replacement CVRs) in exchange for previously issued CVRs and promissory notes [2]. - The company is allowed to issue up to US$1,000,000 of additional 2025 CVRs after July 30, 2027, and up to US$7,000,000 of new Resubmission CVRs if additional funds are needed [2]. Group 3: Distribution of Claim Proceeds - Any proceeds from the arbitration proceedings will be distributed in a specific order: first to settle outstanding trade payables and legal fees, then to repay holders of 2025 CVRs and Resubmission CVRs, and finally to residual claimants [3]. - The distribution of the remaining claim proceeds will be allocated as follows: 5% to management incentive plan participants, 85% to 2025 CVR holders, 9.7% to Replacement CVR holders, and 0.3% to the company [3][4]. Group 4: Board Approval and Governance - The board of directors conducted a thorough review of the private placement, considering alternative financing options, and determined that the company was eligible to rely on exemptions from minority approval requirements [5]. Group 5: Company Profile - Eco Oro is a publicly traded company focused on its arbitration case against the Republic of Colombia, which is central to its operations [6].

Core Viewpoint - SUNation Energy Inc. announced a final cash distribution of $0.12 per non-transferable Contingent Value Right (CVR) to its holders, fulfilling its payment obligations and simplifying its capital structure [1][2]. Group 1: Final Distribution Details - The total final payment amounts to $276,000.48, which will be distributed to all CVR holders starting on or about December 5, 2025 [2]. - Following this payment, the Contingent Value Rights Agreement will terminate, and the CVRs will expire without any further compensation [2]. Group 2: Company Operations and Strategy - SUNation Energy focuses on providing sustainable solar energy and backup power solutions to households, businesses, and municipalities, and aims to grow its presence in the solar and energy services market [1][4]. - The company has made significant operational improvements over the past two years, including cost reductions, debt elimination, and enhanced efficiencies while maintaining high customer service levels [2].

Core Viewpoint - Quantum BioPharma Ltd. announces the expiration of 53,147 warrants and reiterates the record date for the distribution of contingent value rights (CVRs) to shareholders, linked to ongoing litigation against financial institutions for alleged stock price manipulation [1][2][3]. Group 1: Warrants Expiration - The company has expired 53,147 warrants, which were part of a previous financing completed on October 20, 2020, and represents the last tranche issued to hedge funds and investment funds [1]. - The original number of warrants issued was 3,454,543 before a reverse stock split of 65 to 1 [1]. Group 2: Contingent Value Rights (CVRs) - The record date for the distribution of CVRs is set for October 27, 2025, on a one-for-one basis for holders of Class B Subordinate Voting Shares [2]. - Each CVR will entitle holders to a pro rata portion of a minimum of 10% and up to 50% of the net proceeds from the company's legal action against CIBC World Markets, RBC Dominion Securities, and others, which seeks damages exceeding USD $700 million [3][4]. - Payments under the CVRs will only occur if the company receives net proceeds from the litigation, and there is no guarantee that any proceeds will be received [5][8]. Group 3: Company Overview - Quantum BioPharma is focused on developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders, with drug candidates at various stages of development [6]. - The company’s lead compound, Lucid-MS, is designed to prevent and reverse myelin degradation, a key mechanism in multiple sclerosis, and is currently in preclinical models [6]. - Quantum BioPharma retains a 20.10% ownership stake in Unbuzzd Wellness Inc., which is involved in the development of health products, and has a royalty agreement that provides 7% of sales until total payments reach $250 million, after which the royalty rate drops to 3% [6].